| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
You are here > Biopharmaceutical Glossary Homepage/Search > Technologies > Drug delivery & formulation Drug
delivery & formulation
glossary & taxonomy
Applications Map Informatics map Technologies map Biology map Finding guide to terms in these glossaries Site Map Related glossaries include Drug Discovery & development active transport: IUPAC adjuvant: IUPAC bioavailability: IUPAC bioequivalence: IUPAC biologics delivery:
Sessions included penetration and
distribution, selective targeting of tumors, engineering for delivery, delivery
of antibodies, clinical challenges with RNAi therapeutics, novel formulations
for RNAi delivery, and novel approaches for targeted delivery.
Delivery of Biologics Molecular Medicine conference Feb 3-5, 2010 • San
Francisco, CA Program | Order
CD | Download Brochure biologics formulation:
Covers
the latest trends and challenges in biologics formulation and development with a
focus on: improving time to market via early formulations and characterization,
overcoming aggregation challenges, utilizing enabling analytical methodologies,
using experimental design and high-throughput principles, and improving
convenience and compliance through delivery technologies. Optimizing
Biologics Formulation Development
January 11-12, 2010 • Coronado, CA Program | Register | Download Brochure
Part of PepTalk 2010 2009 Sessions included Preformulation and early characterization, predictive tools for formulation development, formulation composition, screening and optimization, process, production and delivery challenges for protein therapeutics. Optimizing Biologics Formulation PepTalk Jan 2009 biopharmaceutics: IUPAC blood brain barrier: Achieving blood-brain barrier (BBB) penetration remains a significant hurdle for successfully prosecuting CNS targets. Decades of research have failed to yield a single “sure-fire” approach to ensure CNS penetration. The current state of CNS drug discovery suggests that a more holistic approach is necessary, one that considers a balance of ADME and physicochemical properties. Dealing with the Blood-Brain Barrier DVD, Molecular Medicine 2010 CNS diseases are a major focus of the pharmaceutical industry, with CNS drugs representing some of its most successful products. However, drug discovery and development researchers experience difficulty developing CNS drugs that complete clinical trials and win regulatory approval—especially drugs which meet major unmet needs in the CNS area, such as Alzheimer’s disease. The vast majority of drugs fail to cross the BBB, which is causing a major bottleneck in successful development of CNS drug candidates. Blood Brain Barrier Overview, Insight Pharma Reports, 2008 dosage form: IUPAC drug delivery: Increasingly, drugs in clinical development incorporate some sort of specialized delivery technology that couples therapeutic benefit with greater ease of use. The demand for this enhanced product profile is changing the way the pharmaceutical industry approaches the discovery, development, and delivery of new medicines. William Heath, vice president of product research and development at Eli Lilly and Company, talked to eCliniqua about the rise in clinical trial activity around new modes of drug delivery. Lilly: Innovation and drug delivery, eCliniqua 2009 drug delivery system: IUPAC drug eluting stent: IUPAC formulation: IUPAC gene therapy: IUPAC liposome: IUPAC lyophilization: Covered the latest trends and challenges in lyophilization, spray drying, and foam drying with a focus on: developing a scientifically sound formulation, optimizing the lyophilization process, successful cycle development and process control, strategies for scale-up from R&D to production, vaccine and biologics freeze/thaw and formulation, container/closure systems, and overcoming tech transfer challenges. Lyophilization & Spray Drying 2010: Strategies for Successful Formulation, Cycle Development and Optimization, Regulatory Compliance, Validation, and Scale Up micelles: IUPAC nanoparticles: IUPAC ophthalmological delivery: Because nothing that concerns intervention with the visual system is trivial, highly innovative specialist companies dominate development on the pharmacological as well as on the drug delivery side, which is immensely important in ophthalmological medicine. Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets, Insight Pharma Reports, 2008 parenteral: IUPAC pharmaceutics: IUPAC pharmacodelivery: Site-directed pharmacodelivery is a desirable but elusive goal. Endothelium and epithelium create formidable barriers to endogenous molecules as well as targeted therapies in vivo. Deidre P. MacIntosh et. al, Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery, PNAS 99 (4): 1996-2001, Feb. 19, 2002 http://www.pnas.org/cgi/content/full/99/4/1996 polymorph:
IUPAC preformulation: IUPAC prodrug: IUPAC [from pharma bio] protein
aggregation: Sessions include mechanistic
perspectives on aggregation, tools and methods for analysis, and approaches for
preventing or managing aggregation,
Protein
Aggregation in Biopharmaceutical Products May 19-20, 2010 • Boston, MA Program | Register | Download Brochure Conference
covered the latest trends and challenges with a focus on: understanding
and controlling protein aggregation, improving detection and quantitation of
aggregates, analyzing subvisible and visible particles with various techniques,
utilizing complimentary technologies for characterization, developing approaches
for rational design/protein engineering of aggregation-resistance for proteins,
understanding aggregates as an inducing factor in immungenicity, improving
structural analysis and modeling to predict protein aggregation, and
understanding the impact of primary sequence and refolding potential on
aggregation. Protein
Aggregation:
Understanding and Overcoming Analytic, Formulation, Manufacturing, and
Regulatory Challenges”, PepTalk 2010 protein delivery: Increasing the success rate of novel therapeutic entities involves anticipating drug delivery routes and considerations early in discovery. Innovative drug delivery approaches will expand the biologics pipeline, and improve properties of biologic drugs. Engineering approaches can enhance pharmacokinetic properties to make possible non-traditional delivery routes for proteins, such as transdermal, oral, inhalation. Engineering Protein Therapeutics for Delivery PEGs April 2009, Boston MA order CD It is a safe bet that if a therapeutic protein is bringing in big money and its patent is nearing expiration, someone somewhere with a clever technology is planning a market invasion based on improving how the protein is delivered. Insight Pharma Reports Delivery Technologies for Protein Therapeutics: Assessment and Outlook 2007 protein therapeutics delivery: See protein delivery RNAi therapeutics delivery: Interfering RNA (RNAi) offers tremendous therapeutic promise to silence genes that give rise to bad, proteins and, therefore, disease. Many products have already reached the market to test the promise that RNAi holds. As RNAi technology progresses, many companies are now trying to increase their shares in the research market by shifting some of their resources to in vitro and in vivo work. The real prize, however, is in therapeutics. RNAi Therapeutics: Challenges in Drug Development and Delivery, Insight Pharma Reports 2005
vaccine
adjuvants and delivery: Sessions include Toll Like
Receptor Technology, Enhancing the Immune Response, DNA vaccines, Modes of
delivery, Particulate delivery and Innovations to enhance safety.
Novel Vaccines:
Adjuvants & Delivery Systems August 18-19, 2010 • Cambridge, MA Program | Register | Download Brochure vaccines delivery: Sessions included adjuvant breakthroughs & successes, Toll Like Receptors TLRs Novel Vaccines: Adjuvants & Delivery systems Aug 2009 Providence RI Order CD Bibliography IUPAC definitions are reprinted with the permission of the International Union of Pure and Applied Chemistry. |
Contact
| Privacy Statement |
Alphabetical
Glossary List | Tips & glossary
FAQs | Site Map
